Syndax Pharmaceuticals Inc. has outlined its strategic position for continued growth, highlighting two exceptional product launches that have surpassed sales expectations. The company targets a $10 billion market opportunity across relapsed/refractory and frontline indications, with two first- and best-in-class medicines addressing significant unmet needs. Notably, the presentation emphasizes the success of Revuforj® (revumenib), the first and only FDA-approved menin inhibitor for treating adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation. Additionally, Syndax has achieved key milestones, including the submission of a supplemental New Drug Application (sNDA) for relapsed/refractory mNPM1 acute myeloid leukemia $(AML.AU)$ and gaining a listing in clinical guidelines for this indication. You can access the full presentation through the link below.